AIM ImmunoTech Inc. — Director's Dealing 2018

Oct 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-10-17

Reporting Person: STRAYER DAVID R (Chief Science/Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-17	Options to buy Common Stock	$0.22	A	123106	Acquired	2028-10-17	Common Stock (123106)	Direct

Footnotes

F1: This option is being issued to senior management in exchange for a voluntary 50% deferral in salary.